Inquiry Basket
Loading ......
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is one of the most economically significant pathogens affecting global swine production. It is an enveloped, positive-sense single-stranded RNA virus belonging to the family Arteriviridae. Since its emergence, PRRSV has caused persistent outbreaks characterized by reproductive failure in breeding pigs and severe respiratory disease in growing pigs.
Globally, PRRSV is classified into two distinct species:
Within these species, the virus is further categorized into distinct genetic lineages (e.g., Lineage 1, Lineage 8, Lineage 9) based on the highly variable ORF5 sequence. In recent years, emerging highly pathogenic strains (HP-PRRSV, Lineage 8) and recombinant field strains (such as NADC30-like and NADC34-like strains within Lineage 1) have caused massive outbreaks, rendering old control strategies ineffective.
PRRSV infection manifests as two major clinical syndromes: reproductive failure in breeding herds (characterized by late-term abortions, stillborn fetuses, mummified piglets, and weak-born piglets) and respiratory disease in growing pigs (presenting as dyspnea, coughing, interstitial pneumonia, and reduced growth performance). Secondary bacterial infections frequently exacerbate clinical outcomes, leading to substantial economic losses from increased mortality, medication costs, and production inefficiency.
Fig. 1 PRRSV infection and replication cycle in host cells
The virus exhibits strict tropism for cells of the monocyte-macrophage lineage, with porcine alveolar macrophages (PAMs) serving as the primary target in the lungs. PRRSV utilizes multiple cellular factors for entry, including CD163 (the essential fusion receptor), sialoadhesin, CD151, vimentin, heparan sulfate, and MYH9. This restricted cellular tropism underpins the virus's ability to establish persistent infection and evade host immune clearance.
PRRSV contains a genome of approximately 15 kb encoding non-structural proteins (ORF1a/1b) and structural proteins including GP2, GP3, GP4, GP5, M protein, and nucleocapsid protein (N).
Major Structural Proteins:
Fig. 2 PRRSV virion structure
PRRSV is well known for its ability to evade and suppress host immunity. One of the most critical features is the delayed production of neutralizing antibodies, which often appear weeks after infection. This delay allows the virus to establish systemic infection before effective immune clearance occurs.
PRRSV also suppresses type I interferon responses and alters cytokine signaling pathways, resulting in weakened antiviral defense. In some cases, antibody-dependent enhancement (ADE) has been observed, where sub-neutralizing antibodies facilitate viral entry into macrophages.
These immune evasion strategies contribute to persistent infection and incomplete protection across different viral strains.
Utilizes a live, attenuated strain of the virus that actively replicates within the host to mimic a natural infection without causing severe clinical disease.
Pros: Strong Immunogenicity. Highly effective at inducing both humoral and cell-mediated immunity, significantly reducing clinical severity against homologous (genetically similar) strains.
Cons: High Biosafety Risks. Carrying a persistent risk of reversion to virulence via mutation or genetic recombination with wild field strains, alongside limited heterologous cross-protection.
Employs physical or chemical agents to completely destroy viral infectivity while preserving the basic structural integrity of the virion.
Pros: Excellent Safety Profile. Zero risk of viral shedding, mutation, or field recombination, making it highly stable for boosting maternal antibodies in pregnant breeding herds.
Cons: Low Immune Potency. Fails to stimulate robust cytotoxic T-lymphocyte (CTL) responses or high-titer neutralizing antibodies on its own, requiring heavy adjuvant pairing.
Focuses the host immune system exclusively on targeted viral antigens, completely eliminating non-essential or potential ADE-inducing viral components.
Antigen Targets: Historically centered on major targets like GP5, M, and N proteins, with next-generation pipelines heavily targeting the GP2a/GP3/GP4 structural protein complex to block cellular entry.
The Bottleneck: Recombinant proteins often struggle to replicate native, quaternary virion conformations, which can limit their ability to induce durable, high-titer neutralizing immunity.
Delivers the exact genetic sequences of conserved PRRSV antigens directly into host cells, forcing the host to synthesize the viral proteins in vivo.
Delivery Systems: Leverages live viral vectors (e.g., modified adenovirus) or encapsulates nucleic acids within biodegradable lipid nanoparticles (LNPs).
Pros: Highly agile formulation updates that closely mimic natural viral replication, successfully driving both MHC Class I and Class II pathways to trigger balanced cellular memory.
Cons: High Manufacturing and Logistical Costs. Nucleic acid platforms require specialized production processes and cold-chain stability, with variable in vivo transfection efficiency across outbred swine populations. Field validation for veterinary applications remains limited compared to established MLV platforms.
Despite widespread use, currently licensed PRRSV vaccines face several fundamental limitations that restrict their field performance:
| Limitation Parameter | Impact on Field Performance | Biological Driver |
| Antigenic Variability | Complete vaccine failure against newly introduced field strains. | High mutation rate and frequent recombination of the ssRNA genome. |
| Limited Cross-Protection | Protection is restricted strictly to homologous or near-identical lineages. | High genetic divergence between PRRSV-1, PRRSV-2, and sub-lineages. |
| Incomplete Neutralizing Response | Delayed and low-titer antibody generation post-vaccination. | Glycan shielding of primary neutralizing epitopes on GP5. |
| Immune Escape Under Pressure | Emergence of vaccine-resistant mutant field strains in heavily vaccinated areas. | Selective evolutionary pressure driving mutations in variable epitope regions. |
| Lack of Sterilizing Immunity | Vaccinated animals can still become infected, shed virus, and become persistent carriers. | Inability of current formulations to trigger robust mucosal and immediate systemic clearance. |
To overcome these limitations and validate new vaccine candidates, a suite of highly specific, repeatable immunological assays is mandatory:
Virus Neutralization (VN) Assays: The gold standard method used to determine vaccine potency and measure the functional protective efficacy of candidate formulations.
ELISA-Based Antibody Detection Systems: High-throughput screening platforms utilizing immobilized recombinant antigens (primarily N or GP5 proteins) to rapidly detect and quantify total anti-PRRSV antibodies in herd samples.
Epitope Mapping of GP5 and M Proteins: A precise profiling method used to pinpoint target amino acid sequences, effectively distinguishing true neutralizing targets from immune-evading decoy epitopes.
Macrophage Infection and Replication Assays: In vitro cell models utilizing primary Porcine Alveolar Macrophages (PAMs) to assess how effectively a vaccine formulation blocks viral entry, transcription, and progeny release.
Cytokine and Immune Profiling Studies: Assays designed to measure critical signaling molecules (e.g., IFN-γ, IL-10) to verify whether a vaccine candidate successfully triggers a protective cellular immune response.
High-quality research reagents are essential for advancing PRRSV vaccine development. Recombinant antigens such as GP5, M, and N proteins are widely used in diagnostic and research applications.
Monoclonal antibodies enable precise detection of viral proteins and support neutralization studies. Polyclonal antibodies provide broader reactivity for immune profiling and assay development.
These reagents are essential for ELISA kits, neutralization assays, and functional immunological studies.
Future research is focused on developing broadly protective and more stable vaccine platforms. Key directions include:
PRRSV remains a complex and evolving viral pathogen due to its genetic diversity, immune evasion strategies, and ability to establish persistent infection in swine populations.
Effective control of PRRSV will require not only improved vaccine platforms but also integrated research tools that enable precise immune characterization and assay development. Recombinant antigens, monoclonal antibodies, and functional assay systems play a central role in accelerating vaccine innovation and translational research.
References
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| PRRSV | DAG-WT806 | Recombinant PRRSV N-NSP7 Fusion Antigen | E. coli | TBD | Immunoassays | Inquiry |
| DAG-WT1143 | Recombinant PRRSV GP5 Protein [His] | E. coli | His | ELISA, WB | Inquiry | |
| DAGC754 | Recombinant PRRSV GP5 Protein [His] | Baculovirus | His | ELISA | Inquiry | |
| DAGA-2015 | Recombinant HP-PRRSV Nucleocapsid Protein [His] | E. coli | His | ELISA, WB | Inquiry | |
| DAGA-2016 | HP-PRRSV nsp7 (aa 2051-2308) [His] | E. coli | His | ELISA, WB | Inquiry |
| Target | Cat. No. | Product Name | Size | Species | Application | Detection Sample | |
| CD151 | DEIA-BJ1013 | Human Cluster of Differentiation 151 ELISA kit | 96T | Quantitative | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate | Inquiry | |
| CD163 | DIA-XYA172 | CD163 ELISA Kit | 96T | Quantitative | Cell lysates, serum, plasma | Inquiry | |
| DEIA-BJ2381 | Mouse sCD163/soluble Haemoglobin Scavenger Receptor ELISA Kit | 96T | Quantitative | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate | Inquiry | ||
| DEIA3000 | Human sCD163(Soluble Cluster of Differentiation 163) ELISA Kit | 96T | Human | Quantitative | Serum, plasma, tissue homogenates and other biological fluids. | Inquiry | |
| MYH9 | DEIA-FN954 | Human MYH9 (Myosin-9) ELISA Kit | 96T | Quantitative | Serum, plasma, cell culture supernatants, tissue homogenate | Inquiry |
Loading ......
